Case report
Open access
Aug 2026
Case Report: Lorlatinib combined with chemotherapy and anti-angiogenic therapy shows promising efficacy in an ALK gene fusion lung adenocarcinoma patient with iruplinalkib resistance
Switching to third-generation TKI lorlatinib in combination with chemotherapy and anti-angiogenic treatment may serve as a potential therapeutic option for overcoming acquired resistance and curbing rapid disease progression in patients with NSCLC.
Mengqing Cao, Shu-Min Li, Linfeng Cao et al.
· Frontiers in Pharmacology · 0 citations